BioSpace News Archive

Quanta Therapeutics, Inc., a privately-held biopharmaceutical company pioneering complex-directed therapies to treat RAS-driven cancer types, today announced that it has successfully closed a $60 Million Series C financing round led by Surveyor Capital (a Citadel company) and Vida Ventures.

Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the Credit Suisse 30th Annual Healthcare Conference on Tuesday, November 9, 2021.

Akoya Biosciences, Inc. (NASDAQ: AKYA) (“Akoya”), The Spatial Biology Company®, today announced the appointment of Pascal Bamford, PhD, as Senior Vice President, Research and Development and Laboratory Operations.

Selecta Biosciences, Inc. (Nasdaq: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a collaboration to design novel and improved enzymes with transformative therapeutic potential to advance treatments for orphan and rare diseases.

Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), an emerging global drug discovery company identifying small and large molecule therapeutics to treat central nervous system (CNS) and oncology-related diseases, announced today the appointment of Robert T. Fremeau Jr., Ph.D., as Chief Scientific Officer.

BioRestorative Therapies, Inc., a life sciences company focused on stem cell-based therapies, announced the nomination of two new independent members to its Board of Directors with industry and medical device experience: Patrick F. Williams, Chief Financial Officer at STAAR Surgical, and David Rosa, President and Chief Executive Officer at NeuroOne.

Quotient Limited, a commercial-stage diagnostics company, announced that financial results for its fiscal second quarter ended September 30, 2021 will be released before market open on Tuesday, November 9, 2021.

Mereo BioPharma Group plc (NASDAQ: MREO), “Mereo” or the “Company”, a clinical stage biopharmaceutical company focused on oncology and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to alvelestat for the treatment of alpha-1 antitrypsin deficiency (AATD).

PTC Therapeutics, Inc. announced that management will present a company overview at the Credit Suisse 30th Annual Healthcare Conference on Tuesday, Nov. 9 at 8:00 a.m. ET.

Harmony Biosciences Holdings, Inc. today announced that it will issue a press release on the Company’s third quarter 2021 financial results on Tuesday, November 9, 2021.